Barclays Maintains an 'Underweight' on Arena Pharma (ARNA); Reports 4Q, Uncertainty Persists
Tweet Send to a FriendGet Alerts ARNA Hot Sheet
Price: $8.06 +1.77%
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
3 Buy, 8 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade ARNA Now!
Barclays maintains an 'Underweight' on Arena Pharma (NASDAQ: ARNA), PT $1.
Barclays analyst says, "We are maintaining our 3-Underweight rating on shares of ARNA following release of 4Q10 operating results and on guidance for 2011. With primary focus on steps towards CRL response and refiling of the lorcaserin NDA, uncertainty has increased with pilot studies still ongoing to guide initial 3-month pre-clinical prolactin mechanistic studies and with the FDA now suggesting consideration of a 12-month rat carcinogenicity study. Visibility on re-adjudication of mammary cancers in rats and on protocols to address pre-clinical astrocytoma risk remains poor and new questions on valve safety persist following BLOOM-DM data. We continue to expect extended timelines for NDA resubmission and believe that likelihood of lorcaserin approval is low." (Barclays raises FY11 EPS estimates from -0.82 to -0.68)
For more ratings news on Arena Pharma click here and for the rating history of Arena Pharma click here.
Shares of Arena Pharma closed at $1.51 yesterday, with a 52 week range of $1.26-$8.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays analyst says, "We are maintaining our 3-Underweight rating on shares of ARNA following release of 4Q10 operating results and on guidance for 2011. With primary focus on steps towards CRL response and refiling of the lorcaserin NDA, uncertainty has increased with pilot studies still ongoing to guide initial 3-month pre-clinical prolactin mechanistic studies and with the FDA now suggesting consideration of a 12-month rat carcinogenicity study. Visibility on re-adjudication of mammary cancers in rats and on protocols to address pre-clinical astrocytoma risk remains poor and new questions on valve safety persist following BLOOM-DM data. We continue to expect extended timelines for NDA resubmission and believe that likelihood of lorcaserin approval is low." (Barclays raises FY11 EPS estimates from -0.82 to -0.68)
For more ratings news on Arena Pharma click here and for the rating history of Arena Pharma click here.
Shares of Arena Pharma closed at $1.51 yesterday, with a 52 week range of $1.26-$8.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
- Topeka Capital Starts Spansion (CODE) at Buy
- Topeka Capital Starts InvenSense (INVN) at Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
